CervoMed Inc

Phase 2b data show CervoMed’s neflamapimod improves cognition and neuropsychiatric symptoms in DLB, driving a 50 % stock jump and opening a potential first‑in‑class therapy.

CervoMed Inc. is a clinical-stage biotech company working to develop treatments for neurodegenerative disorders, navigating the challenges and opportunities of the biotech sector.

CervoMed Inc. is a clinical-stage biotech company pioneering neurodegenerative treatment innovation, with a promising pipeline and strategic initiatives to address complex central nervous system disorders.